z-logo
Premium
Prostaglandin E 2 promotes hepatic bile acid synthesis by an E prostanoid receptor 3‐mediated hepatocyte nuclear receptor 4α/cholesterol 7α‐hydroxylase pathway in mice
Author(s) -
Yan Shuai,
Tang Juan,
Zhang Yuyao,
Wang Yuanyang,
Zuo Shengkai,
Shen Yujun,
Zhang Qianqian,
Chen Di,
Yu Yu,
Wang Kai,
Duan ShengZhong,
Yu Ying
Publication year - 2017
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.28928
Subject(s) - cholesterol 7 alpha hydroxylase , medicine , endocrinology , liver x receptor , ldl receptor , g protein coupled bile acid receptor , nuclear receptor , hepatocyte , hepatocyte nuclear factor 4 , farnesoid x receptor , cholesterol , chemistry , bile acid , biology , lipoprotein , biochemistry , gene , transcription factor , in vitro
Prostaglandin E 2 (PGE 2 ) is an important lipid mediator of inflammation. However, whether and how PGE 2 regulates hepatic cholesterol metabolism remains unknown. We found that expression of the PGE 2 receptor, E prostanoid receptor 3 (EP3) expression is remarkably increased in hepatocytes in response to hyperlipidemic stress. Hepatocyte‐specific deletion of EP3 receptor ( EP3 hep–/– ) results in hypercholesterolemia and augments diet‐induced atherosclerosis in low‐density lipoprotein receptor knockout ( Ldlr –/– ) mice. Cholesterol 7α‐hydroxylase (CYP7A1) is down‐regulated in livers of EP3 hep–/– Ldlr −/− mice, leading to suppressed hepatic bile acid (BA) biosynthesis. Mechanistically, hepatic‐EP3 deficiency suppresses CYP7A1 expression by elevating protein kinase A (PKA)‐dependent Ser143 phosphorylation of hepatocyte nuclear receptor 4α (HNF4α). Disruption of the PKA‐HNF4α interaction and BA sequestration rescue impaired BA excretion and ameliorated atherosclerosis in EP3 hep–/– Ldlr −/− mice. Conclusion : Our results demonstrated an unexpected role of proinflammatory mediator PGE 2 in improving hepatic cholesterol metabolism through activation of the EP3‐mediated PKA/HNF4α/CYP7A1 pathway, indicating that inhibition of this pathway may be a novel therapeutic strategy for dyslipidemia and atherosclerosis. (H epatology 2017;65:999‐1014)

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom